AUA Expert Exchange Podcast: Discussion in GU Cancer (2021)
To encourage consistent, high quality, evidence-based treatment of patients, the AUA has developed a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Based on the documented need for additional education in prostate cancer, bladder cancer, and renal cell carcinoma, the AUA will identify expert faculty to engage in a series of eight interactive interview-style episodes. This expert exchange delivered via podcast is designed to address very specific learning opportunities and reach urologists in an easy, flexible way with smaller, targeted updates.
The 8 topic-specific podcasts will focus on the following:
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update
- Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer
- Identification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer
- Novel Imaging for High Risk Prostate Cancer
- Advances in Immuno-Oncology in Urothelial Carcinoma
- Management of Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies
- Peer-Reviewed Guidance on How to Recognize and Manage Immune-Related Adverse Events & Toxicities
- How to Safely and Properly Administer Immunotherapies
This educational series is supported by independent educational grants from:
- Lantheus Medical Imaging
- Pfizer, Inc.
At the conclusion of these activities, participants will be able to:
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update
- Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced Prostate Cancer Guideline encompassing metastatic and CRPC disease.
- Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer
- Analyze the risks and benefits of treatment for M1 HSPC, MO CRPC and M1 CRPC.
- Differentiate the clinical significance of GnRH agonists vs. GnRH antagonists and newer treatments in that complement (anti-androgens, chemotherapy) these options.
- Facilitate discussions with patients and caregivers regarding treatment options.
Identification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer
- Oversee comorbidities and describe their management in the context of prostate cancer treatment.
- Differentiate the roles of the urologist, other specialists and primary care provider and identify opportunities for shared care and team-based approaches of patients with prostate cancer.
Novel Imaging for High Risk Prostate Cancer
- Review clinical trials and available PET imaging agents for the detection of prostate cancer.
- Assess the indications, risks and benefits of incorporating PET imaging to guide treatment for men with recurrent prostate cancer.
Advances in Immuno-Oncology in Urothelial Carcinoma
- Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma.
- Prioritize treatment options in first line metastatic urothelial carcinoma.
- Evaluate second line options for metastatic urothelial carcinoma.
Management of Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies
- Discuss the current targeted and immunotherapy options available for the treatment of RCC.
- Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
- Describe best practices in RCC patient selection for treatment options.
- Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.
Peer-Reviewed Guidance on How to Manage Immune-Related Adverse Events & Toxicities
- Discuss the current evidence-based literature associated with adverse events and toxicity associated with immunotherapies.
- Identify and manage the adverse events related to immunotherapies.
How to Safely and Properly Administer Immunotherapies
- Identify current IO treatment barriers associated with the proper administration of IO therapies including the implementation of in an infusion suite.
- Develop an infrastructure to monitor patients for side effects and potential complications.
- Identify the proper candidates for treatment and better counsel patients on the pros and cons of therapy.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 4.0 hours
Release Date: October, 2021
Expiration Date: December, 2022
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.